$ARTV earnings report

Artiva discontinues AlloNK development, reduces its workforce by approximately 94% and begins a strategic-alternatives review following durability concerns and two Grade 5 events. AlphAI read Artiva Biotherapeutics's quarter ended September 30, 2026 filing as weak.

quarter ended September 30, 2026

AlphAI · Earnings readARTV · quarter ended September 30, 2026 · ended September 30, 2026

Artiva discontinues AlloNK development, reduces its workforce by approximately 94% and begins a strategic-alternatives review following durability concerns and two Grade 5 events.

↓Weak quarter

The Company has halted all further development of its sole disclosed lead candidate, will not initiate the planned Phase 3 pivotal trial, is reducing its workforce by approximately 94%, and is evaluating alternatives that include dissolution and liquidation.

Key metrics

as reported
MetricValueq/qy/y
Cash, cash equivalents and investments as of September 30, 2026otherapproximately $319.1 million––

What drove it

  • Updated clinical response data continued to demonstrate deep B cell depletion and clinical activity consistent with previously reported findings.
  • Longer-term follow-up did not reflect the level of durability of clinical response the Company believes is needed to support continued development.
  • The Company assessed the overall risk-benefit, likely enrollment delays, and the overall development and potential commercial outlook.
  • Artiva is reducing its workforce by approximately 94% to preserve capital while evaluating strategic alternatives.

Concerns

  • Artiva is discontinuing further development of AlloNK (AB-101), and no additional patients will be dosed in any ongoing AlloNK clinical study.
  • The planned Phase 3 pivotal trial will not be initiated.
  • A participant in the Phase 2a basket trial experienced a fatal neurological event, leukoencephalopathy, that the investigator and an independent safety review assessed as likely related to fludarabine-associated neurotoxicity.
  • A second participant experienced sudden death approximately two months after initiating study treatment; the investigator assessed the event as unrelated to AlloNK or any other component of the study treatment regimen, and the cause of death has not been determined.
  • The FDA asked Artiva to pause enrollment and dosing in the Phase 2a study following notification of the fludarabine-associated event.
  • There can be no assurance that the strategic review will result in a transaction or particular outcome.
  • The preliminary cash balance is unaudited and subject to adjustment.

What to watch

  • The outcome of the Board of Directors' evaluation of a merger, business combination, sale or licensing of assets, dissolution and liquidation.
  • The timing and operational impact of the workforce reduction and related activities.
  • The orderly close-out of the clinical development program, including continued safety monitoring and reporting.
  • Whether Artiva publishes the fludarabine-associated neurotoxicity case or presents updated clinical data at a future scientific meeting.
  • Final quarterly results in Artiva's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

Balance sheet and cash flow

  • Cash, cash equivalents and investments of approximately $319.1 million (preliminary and unaudited) as of September 30, 2026.
  • The preliminary cash, cash equivalents and investments as of September 30, 2026 are unaudited and subject to adjustment.

Analysis

This filing is a strategic update rather than a complete quarterly earnings release. Artiva has discontinued further development of AlloNK (AB-101), its allogeneic NK cell therapy candidate, and will neither dose additional patients in ongoing AlloNK studies nor initiate the planned Phase 3 pivotal trial. The Company said updated data continued to show deep B cell depletion and clinical activity consistent with prior findings, but longer-term follow-up did not meet its required threshold for durability of clinical response.

Safety and the clinical risk-benefit profile drove the decision. One Phase 2a basket-trial participant experienced a fatal neurological event, leukoencephalopathy, which the investigator and an independent safety review assessed as likely related to fludarabine-associated neurotoxicity. A second participant experienced sudden death approximately two months after initiating treatment; the investigator assessed that event as unrelated to AlloNK or any other component of the study treatment regimen, and the cause has not been determined. The FDA asked the Company to pause enrollment and dosing in the Phase 2a study after the first event was reported.

The corporate response is a substantial restructuring. Artiva is reducing its workforce by approximately 94% to preserve capital and has engaged Leerink Partners as financial advisor while its Board evaluates strategic alternatives. Potential paths expressly include a merger, business combination, sale or licensing of assets, dissolution and liquidation. The Company also cancelled its investor webcast scheduled for November 9, 2026 and no longer plans to present previously announced clinical data at ACR Convergence 2026.

Liquidity disclosed in the release was approximately $319.1 million in cash, cash equivalents and investments as of September 30, 2026. That amount is preliminary, unaudited and subject to adjustment. The filing provides no revenue, expense, loss, EPS, cash-flow, debt, share-repurchase, dividend or forward financial guidance figures; complete quarterly results are expected in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

The principal watch items are the final September 30 financial statements, the costs and execution of the workforce reduction and study close-out, continued safety reporting, and any Board-approved strategic outcome. Management stated that it does not intend to provide further updates on the strategic-alternatives process unless the Board approves a specific course of action, the process concludes, or further disclosure is appropriate or required by law.

Management, verbatim

After careful consideration, we have made the difficult decision to discontinue development of AlloNK and to pursue strategic alternatives.

Fred Aslan, M.D., chief executive officer of Artiva Biotherapeutics

Throughout the development of AlloNK, the safety and well-being of patients have remained our highest priority. We are deeply saddened by the deaths of two patients who participated in our clinical studies and extend our sincere condolences to their families.

Fred Aslan, M.D., chief executive officer of Artiva Biotherapeutics

Not in the filing

stated, not guessed
  • Complete quarterly revenue for the quarter ended September 30, 2026.
  • Revenue comparisons and revenue growth rates.
  • Segment revenue and segment comparisons.
  • GAAP gross profit and gross margin.
  • GAAP operating expenses and operating income or loss.
  • GAAP net income or loss.
  • GAAP earnings or loss per share.
  • Non-GAAP financial metrics, including non-GAAP earnings or loss per share.
  • Operating cash flow.
  • Free cash flow.
  • Debt balance.
  • Share repurchases.
  • Dividends.
  • Forward financial guidance.
  • Prior-period guidance for comparison.
  • Final audited or reported cash, cash equivalents and investments balance for September 30, 2026.
  • Detailed workforce-reduction costs, timing and expected savings.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ARTV earnings dates

When is Artiva Biotherapeutics's next earnings date?
AlphAI has no date for ARTV yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.